We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
Results for
"[search-keyword]"
Sponsor content
16 result(s) found, displaying 1 to 10
-
Designation or determinationOrphan Drug
-
Australian Public Assessment Report (AusPAR)Minjuvi (tafasitamab) is provisionally approved for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplants.
-
Designation or determinationOrphan drug
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for MINJUVI tafasitamab 200 mg powder for solution for infusion 1 vial per carton.
-
Australian Public Assessment Report (AusPAR)AusPAR for Pemazyre (pemigatinib) for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or rearrangement that has progressed after at least one prior line of systemic therapy.
-
Prescription medicine decision summaryWe have approved Minjuvi (tafasitamab) to treat diffuse large B-cell lymphoma (DLBCL).
-
Prescription medicine registrationActive ingredients: tafasitamab.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for PEMAZYRE pemigatinib 4.5 mg tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for PEMAZYRE pemigatinib 13.5 mg tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for PEMAZYRE pemigatinib 9 mg tablet blister pack.